Skip to Main Content

WASHINGTON — Pharmaceutical company Johnson & Johnson (JNJ) and insurance giant Aetna (AET) are partnering on “value-based” contracts for diabetes care, a practice executives from the companies discussed during an industry breakfast Tuesday morning.

J&J executive vice president Joaquin Duato said that one of the agreements covers the type 2 diabetes drug Invokana. J&J gives Aetna a rebate if a predetermined percentage of patients have to take additional diabetes medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!